Clinical Trial Update: Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating activated recombinant human factor VII for bleeding in dengue hemorrhagic fever has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Hemorrhagic Fever

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Dengue Haemorrhagic Fever | Phase 2 | Status: COMPLETED